Karolinska Development has celebrated an exit as Umeå spinout Asarina Pharma went public in Sweden after raising $16.3m in its initial public offering.
The immuno-oncology therapy developer's investors include UC’s office of the chief investment officer, which contributed to a $300m round in January.
A month after Sutro closed an $85.4m series E round, the cancer drug developer, based on research at Stanford, has filed for a $75m initial public offering.
Ascentage Pharma, based on research at University of Michigan, has filed to list in Hong Kong having raised about $235m in funding.
Principia Biopharma, whose drug discovery platform is based on research at UCSF, has filed for an $86.3m initial public offering having raised $50m earlier this month.
Sensyne Health has completed a $76m initial public offering and will begin trading on Aim tomorrow, offering an exit to University of Oxford.
The Johns Hopkins-backed antibody developer floated above its range and has seen its stock almost double in price.
The UC Investment Office-backed cancer drug developer cut the number of shares in the offering but priced them at the mid-point of its range.
UCL Technology Fund-backed gene therapy developer MeiraGTx has gone public on Nasdaq after raising $75m in proceeds in its initial public offering.